COMPASS Pathways Archives

Psychedelics News

COMPASS Pathways

Industry

23 Feb 2023

Compass Pathways’ New Psilocybin For Depression Trial, Explained

On February 17th, psychedelic medicine company Compass Pathways (Nasdaq: CMPS) registered a new Phase 2 clinical trial attempting to treat Major Depressive Disorder using psilocybin-assisted therapy....

By James Hallifax

Industry

4 Jan 2023

Top 3 Psychedelic Storylines to Watch in 2023

2022 was a milestone year for the psychedelic industry, and 2023 is shaping up to be an even more paradigm-shifting....

By James Hallifax

Industry

8 Dec 2022

Good Results for COMP360 Psilocybin in Bipolar Disorder Study

Positive study results of COMP360 psilocybin therapy in type II bipolar disorder and analysis of the phase 2b trial of COMP360 psilocybin therapy in treatment-resistant depression....

By Microdose NewsDesk

Industry

9 Aug 2022

Breaking News: Terran Biosciences Sues Compass Pathways for Stealing Trade Secrets

According to the court filings, Compass allegedly entered into negations and signed an NDA with a researcher regarding psilocybin development, before ending the talks and "milking" him for this confidential...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News, Industry

28 Jul 2022

Compass Pathways Launches New Phase 2 Trial for Anorexia

Today we have more positive news, with the firm announcing a new Phase 2 trial using its COMP360 psilocybin for anorexia, taking place at prestigious sites like King's College London...

By Microdose NewsDesk

Don’t Miss

25 Jul 2022

News You Might Have Missed: July 25th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

19 Jul 2022

COMPASS Pathways Appoints Big Pharma CEO

Compass Pathways' George Goldsmith is replaced by Kabir Nath, former Senior Director at pharma giant Otsuka Pharmaceuticals....

By Jason Najum

Industry

27 Jun 2022

Compass Wins Patent Case; MindMed Granted Patent For MDMA and LSD

Compass Pathways and MindMed get patent wins in controversial patent claims...

By Jason Najum

Industry

3 Jun 2022

The Top Clinical Trials in 2022

2022 is expected to be a pivotal year, with the psychedelic industry attempting to solidify itself as a commercially viable endeavor....

By Jason Najum

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result